Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Mitchell Goff

Retina Specialist Salt Lake City, UT Medical Doctor

NPI 1578595153 CMS profile 607236

4400 S 700 E Ste 200, Salt Lake City, UT 84107

Open in the dashboard

General payments

$165,054

290 records reported · program years 2019–2025

Research payments

$7,025

Paid to them · 4 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$1,508,346 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Mitchell Goff of Salt Lake City, UT is reported in the CMS Open Payments database as having received $165,054 across 290 general payments and $7,025 in research payments paid to them. Separately, studies naming them as principal investigator received $1,508,346 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 95th percentile of Retina Specialist profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $9,189 43
2024 General $55,244 62
2023 General $732 24
2022 General $1,371 14
2021 General $7,805 12
2020 General $42,038 54
2020 Research $7,025 4
2019 General $48,676 81

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mitchell Goff
  • Retina Specialist median
  • Middle half of Retina Specialist
  • National median

In program year 2025, general payments to Mitchell Goff were reported at $9,189. Among 1,235 Retina Specialist profiles paid that year, the median was $457 and the middle half received between $175 and $1,079.

Show as a table
Year Mitchell Goff Retina Specialist median Middle half National median
2019 $48,676 $410 $157–$1,517 $163
2020 $42,038 $168 $65–$778 $114
2021 $7,805 $258 $101–$1,161 $132
2022 $1,371 $418 $162–$1,488 $149
2023 $732 $476 $178–$1,312 $160
2024 $55,244 $520 $188–$1,372 $164
2025 $9,189 $457 $175–$1,079 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Regeneron Healthcare Solutions, Inc. $131,829 169 payments
  2. Astellas Pharma US Inc $10,916 34 payments
  3. Regeneron Pharmaceuticals, Inc. $9,042 5 payments
  4. F. Hoffmann-La Roche AG $5,953 2 payments
  5. Genentech USA, Inc. $4,263 37 payments
  6. EyePoint Pharmaceuticals US, Inc. $1,754 6 payments
  7. Harrow Eye, LLC $433 8 payments
  8. Novartis Pharmaceuticals Corporation $220 4 payments
  9. Alimera Sciences, Inc. $139 7 payments
  10. Genentech, Inc. $107 1 payment
  11. Other $398 17 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $87,782 22 payments
  2. Consulting Fee $55,133 25 payments
  3. Travel and Lodging $15,788 65 payments
  4. Food and Beverage $6,320 177 payments
  5. Entertainment $32 1 payment
Products named General payments · program years 2019–2025
  1. EYLEA $93,265 122 payments
  2. EYLEA HD $51,399 55 payments
  3. Izervay $9,759 27 payments
  4. Lucentis $4,147 26 payments
  5. EYP-1901 $1,582 4 payments
  6. TRIESENCE $326 3 payments
  7. IHEEZO $310 7 payments
  8. VABYSMO $273 13 payments
  9. YUTIQ $151 1 payment
  10. OZURDEX $99 3 payments
  11. Other $629 28 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. F. Hoffmann-La Roche AG $7,025 4 payments

Prescribing to Medicare patients

Part D · data year 2024 · 7 drugs

Part D claims

216

Median for Ophthalmology: 891

Drug cost

$11,048

Median for Ophthalmology: $68,233

Branded share of claims

21.3%

Median for Ophthalmology: 29.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Rocklatan Netarsudil Mesylat/Latanoprost Brand 14 $4,613
Simbrinza Brinzolamide/Brimonidine Tart Brand 17 $3,408
Prednisolone Acetate Generic 43 $1,386
Latanoprost Generic 92 $656
Ketorolac Tromethamine Generic 20 $517
Dorzolamide-Timolol Dorzolamide Hcl/Timolol Maleat Brand 15 $256
Timolol Maleate Generic 15 $212

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,260 Part D prescribers listed as Ophthalmology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 46 billing codes

Paid by Medicare

$3,878,592

Of which drugs: $2,651,967

Medicare patients

689

Average age 79

Services billed

24,076

422 women, 267 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 71%
Arthritis 38%
Diabetes 31%
Chronic kidney disease 23%
Ischemic heart disease 21%
Heart failure 19%
Depression 19%
Atrial fibrillation 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, aflibercept hd, 1 mg J0177 Office 232 6,412 $1,687,346
Injection, avacincaptad pegol, 0.1 mg J2782 Office 91 7,260 $625,419
Injection, faricimab-svoa, 0.1 mg J2777 Office 23 4,680 $128,116
Injection, aflibercept, 1 mg J0178 Office 29 186 $122,662
Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg Q5128 Office 14 326 $59,045

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 8 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
EYLEA HD
  • Regeneron Healthcare Solutions, Inc. $34,338
  • Regeneron Pharmaceuticals, Inc. $7,632
$41,970 — 6,412
Izervay
  • Astellas Pharma US Inc $8,502
$8,502 — 7,260
EYLEA
  • Regeneron Healthcare Solutions, Inc. $1,986
$1,986 — 186
IHEEZO
  • Harrow Eye, LLC $39
$39 — —
OZURDEX
  • AbbVie, Inc. $34
$34 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 8 in the dashboard with a free account

Records

294 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Retina Specialist in Utah

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record